Age-Related Fecal Calprotectin Concentrations in Healthy Adults
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Fecal calprotectin (FC) is a marker used for the differential diagnosis of inflammatory bowel disease (IBD). FC is also used to determine the effects of treatment and recurrence prediction because of its non-decomposition by bacteria, relative week stability at room temperature, and its uniform distribution within feces. Healthy male and female adults between the age of 30 and 80 living in Jeju were selected for this study. The FC concentration in the healthy control group (N=45) was distributed widely as 0∼545.9 μg/g and showed a significant difference with age in healthy adults. The FC concentration in adults over 70 years old (80.6 years on average) was 160.3 μg/g. The result is approximately 10 times higher than in adults below 50 years (44 years on average), with FC concentrations at 15.88 μg/g. Moreover, adults over 50 years, with an average age of 59.6, had FC concentrations of 35.46 μg/g, which were two times higher than the below 50-year-old group, confirming the significant correlation between age and FC concentration. As the FC test is a non-invasive and cost-effective objective marker in IBD tests, a suitable cut-off value is required for different ages. This study provides the baseline data for differential diagnoses.
Abstract
Fecal calprotectin (FC) is a marker used for the differential diagnosis of inflammatory bowel disease (IBD). FC is also used to determine the effects of treatment and recurrence prediction because of its non-decomposition by bacteria, relative week stability at room temperature, and its uniform distribution within feces. Healthy male and female adults between the age of 30 and 80 living in Jeju were selected for this study. The FC concentration in the healthy control group (N=45) was distributed widely as 0∼545.9 μg/g and showed a significant difference with age in healthy adults. The FC concentration in adults over 70 years old (80.6 years on average) was 160.3 μg/g. The result is approximately 10 times higher than in adults below 50 years (44 years on average), with FC concentrations at 15.88 μg/g. Moreover, adults over 50 years, with an average age of 59.6, had FC concentrations of 35.46 μg/g, which were two times higher than the below 50-year-old group, confirming the significant correlation between age and FC concentration. As the FC test is a non-invasive and cost-effective objective marker in IBD tests, a suitable cut-off value is required for different ages. This study provides the baseline data for differential diagnoses.
참고문헌 (29)
- Natalie A. Molodecky, "Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review", Gastroenterology, 142(1), pp.46~54 (2012), Elsevier BV[DOI]
- Suk-Kyun Yang, "Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986–2005: A KASID study", Inflammatory Bowel Diseases, 14(4), pp.542~549 (2008), Oxford University Press (OUP)[DOI]
- 이준, "염증성 장질환에서 분변 칼프로텍틴", 대한소화기학회지, 67(5), pp.233~237 (2016), 대한소화기학회
- E F Stange, "European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis", Gut, 55(suppl_1), pp.i1~i15 (2006), BMJ[DOI]
- Cobb WS, "Colonoscopic perforations: incidence, management, and outcomes", Am Surg, 70, pp.750~757 (2004)
- Andrew D. Sutherland, "Review of Fecal Biomarkers in Inflammatory Bowel Disease", Diseases of the Colon & Rectum, 51(8), pp.1283~1291 (2008), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Fagerhol MK, "A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells", Bull Eur Physiopathol Respir, 16, pp.273~282 (1980)[DOI]
- A. G. RØseth, "Assessment of the Neutrophil Dominating Protein Calprotectin in Feces: A Methodologic Study", Scandinavian Journal of Gastroenterology, 27(9), pp.793~798 (2009), Informa UK Limited[DOI]
- Vermeire S, "Laboratory markers in IBD : useful, magic, or unnecessary toys?", Gut, 55, pp.426~431 (2006)[DOI]
- 박신영, "A Study of Fecal Calprotectin in Obese Children and Adults", Journal of Obesity & Metabolic Syndrome, 27(4), pp.233~237 (2018), 대한비만학회
- Røseth A, "Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel Disease", Scandinavian Journal of Gastroenterology, 34(1), pp.50~54 (2009), Informa UK Limited[DOI]
- 이양운, "The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity", The Korean Journal of Internal Medicine, 34(1), pp.72~80 (2019), 대한내과학회[DOI]
- E Olafsdottir, "Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children", Acta Paediatrica, 91(1), pp.45~50 (2002), Wiley[DOI]
- Stina Josefsson, "Fecal Calprotectin in Very Low Birth Weight Infants", Journal of Pediatric Gastroenterology & Nutrition, 44(4), pp.407~413 (2007), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Yang Q, "Dynamic change of fecal calprotectin in very low birth weight infants during the first month of life", Neonatology, 94, pp.267~271 (2008)[DOI]
- 윤정민, "Fecal calprotectin concentration in neonatal necrotizing enterocolitis", Clinical and Experimental Pediatrics, 57(8), pp.351~356 (2014), 대한소아청소년과학회
- P. F. van Rheenen, "Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis", BMJ, 341(jul15 1), pp.c3369~c3369 (2010), BMJ[DOI]
- Athanasios Kostas, "Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease", World Journal of Gastroenterology, 23(41), pp.7387~7396 (2017), Baishideng Publishing Group Inc.[DOI]
- 류인혁, "Fecal Calprotectin as a Useful Non-Invasive Screening Marker for Eosinophilic Gastrointestinal Disorder in Korean Children", Journal of Korean Medical Science, 35(17), pp.1~8 (2020), 대한의학회[DOI]
- Javier P. Gisbert, "Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease", Inflammatory Bowel Diseases, 15(11), pp.1746~1754 (2009), Oxford University Press (OUP)[DOI]
- Seo SC, "Elevated fecal calprotectin levels are associated with severity of atopic dermatitis in children", Asian Pacific Journal of Allergy and Immunology, 36, pp.82~87 (2018), Allergy, Asthma, and Immunology Association of Thailand[DOI]
- Maria Gloria Mumolo, "From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting", World Journal of Gastroenterology, 24(33), pp.3681~3694 (2018), Baishideng Publishing Group Inc.[DOI]
- Gerhard Rogler, "Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion", Journal of Crohn's and Colitis, 7(8), pp.670~677 (2013), Oxford University Press (OUP)[DOI]
- Qingling Zhu, "Fecal Calprotectin in Healthy Children Aged 1-4 Years", PLOS ONE, 11(3), pp.e0150725~ (2016), Public Library of Science (PLoS)[DOI]
- Elin Hestvik, "Faecal calprotectin concentrations in apparently healthy children aged 0-12 years in urban Kampala, Uganda: a community-based survey", BMC Pediatrics, 11(1), pp.9~16 (2011), Springer Science and Business Media LLC[DOI]
- Feng Li, "Fecal Calprotectin Concentrations in Healthy Children Aged 1-18 Months", PLOS ONE, 10(3), pp.e0119574~ (2015), Public Library of Science (PLoS)[DOI]
- Shilpa Joshi, "Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers", Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 47(3), pp.259~263 (2010), SAGE Publications[DOI]
- Giulia C. Leonardi, "Ageing: from inflammation to cancer", Immunity & Ageing, 15(1) (2018), Springer Science and Business Media LLC[DOI]
- Andrew Poullis, "Bowel Inflammation as Measured by Fecal Calprotectin", Cancer Epidemiology Biomarkers & Prevention, 13(2), pp.279~284 (2004), American Association for Cancer Research (AACR)[DOI]